HealthcareBiomarker predicts KRASG12C inhibitor success in lung cancer treatment

Biomarker predicts KRASG12C inhibitor success in lung cancer treatment


Lung cancer
Credit: Anna Tarazevich from Pexels

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two proteins, RAS and RAF, could provide valuable insights into the effectiveness of treatments for patients with KRASG12C-mutant non-small cell lung cancer, a type of lung cancer known for being particularly difficult to treat.

The findings revealed that tumors with higher levels of RAS–RAF protein interaction were more likely to respond to KRASG12C inhibitors, a class of drugs designed to target the KRASG12C mutation. This discovery could help doctors identify which patients are most likely to benefit from this treatment.

The researchers developed a special test, called a proximity ligation assay, to measure how often RAS and RAF interact inside . Their results showed that tumors with stronger RAS–RAF interactions also had higher levels of active RAS signaling, which is linked to better responses to KRASG12C inhibitors.

“Our findings could be a game-changer for treating KRASG12C-mutant NSCLC,” said Ryoji Kato, Ph.D., a postdoctoral fellow in the lab of Eric Haura, M.D. “By measuring RAS–RAF interactions, we can potentially help doctors make more informed decisions and provide better treatment outcomes for patients.”

The study also compared this method with other common markers of cancer activity, like EGFR, and found that EGFR activity did not predict response to the KRASG12C inhibitors. This suggests that RAS–RAF interaction is a more accurate biomarker for treatment response.

“This research opens the door to more personalized cancer treatment,” said Haura, associate center director for Clinical Science at Moffitt. “The ability to assess RAS signaling directly in tumor samples could lead to more targeted therapies and better outcomes for patients with KRAS-mutant cancers.”

The new proximity ligation assay method could become an important tool in clinical settings, helping doctors select the right treatments for the right patients and improving outcomes in a type of cancer that has few effective options.

More information:
Ryoji Kato et al, In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer, Clinical Cancer Research (2025). DOI: 10.1158/1078-0432.CCR-24-3714

Citation:
Biomarker predicts KRASG12C inhibitor success in lung cancer treatment (2025, January 31)
retrieved 31 January 2025
from https://medicalxpress.com/news/2025-01-biomarker-krasg12c-inhibitor-success-lung.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Original Source Link

Latest News

“The Digital Fourth Amendment,” Now Shipping

I'm pleased to say that my new book, The Digital Fourth Amendment, is now available for shipping at...

Astronomers discover ‘Quipu’, the single largest structure in the known universe

Astronomers have discovered what may be the largest-scale structure in the known universe — a group of galaxy...

Handmade Valentine’s Day Crafts for Kids: Simple Ideas for Sweet Home Décor

Valentine’s Day is the perfect day to celebrate love for one another. It’s a great opportunity to let...

How Much Money He Makes in 2024 – Hollywood Life

Bill Belichick has continued to make headlines for his personal life, particularly with his girlfriend, Jordon Hudson, who is 48 years...

Must Read

Stalled Grandpark project returns in Sacramento County, in two pieces

Three months after Sacramento County stopped processing the...

“The Digital Fourth Amendment,” Now Shipping

I'm pleased to say that my new book,...
- Advertisement -

You might also likeRELATED
Recommended to you